OAB and Incontinence

At SUFU 2026, 24-month data from the TITAN 2 trial showed that the Altaviva ITNM system provided sustained reductions in urgency urinary incontinence episodes, durable quality-of-life improvements, and a favorable safety profile through 24 months.

Aleece Fosnight, MSPAS, PA-C, emphasizes that timing is one of the most valuable diagnostic clues.

Hormonal changes influence fluid balance and bloating, increasing pressure within the pelvis.

The safety and efficacy of the Revi System were established in the pivotal OASIS trial.

Aleece Fosnight, MSPAS, PA-C, argues that incontinence must be understood as a common, treatable medical condition rather than a personal failure or an inevitable part of aging.

Sameena A. Rahman, MD, emphasizes that menopause care requires precision medicine rather than a one-size-fits-all approach.

Once patients are ready to explore treatment, Fosnight stresses the importance of shared decision-making.

Aleece Fosnight, MSPAS, PA-C, encouraged urologists to normalize the conversation by openly acknowledging that these discussions can feel embarrassing but also by celebrating patients for taking the first step.

The new CPT code will be effective starting on July 1, 2026.

Aleece Fosnight, MSPAS, PA-C, highlights that although urinary leakage is common, it is not normal—and effective treatment options exist.

This announcement follows positive top-line data from a phase 1b/2a clinical trial of EG110A in patients with NDO following a spinal cord injury.

Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES, emphasized that many older patients eventually pursue care only after years of coping, when their quality of life has been significantly affected.

A recap of the FDA submissions and regulatory decisions in urology from September 2025.

Fosnight described how stigma itself becomes a barrier to care, even though effective diagnostic and treatment options are available.

The Altaviva device is a minimally invasive implantable tibial neuromodulation therapy for patients with urge urinary incontinence.

Fosnight emphasizes that the cycle of shame, secrecy, and loneliness compounds the burden of urinary incontinence far beyond its physical effects.

The tool is designed as a patient-facing application that can be used both during clinic visits and independently at home.

Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES, emphasizes a careful, individualized approach to managing bladder and bowel symptoms in women with a history of disordered eating.

Aleece Fosnight, MSPAS, PA-C, emphasizes that any patient presenting with urinary incontinence or related symptoms should be evaluated for pelvic floor dysfunction.

Findlay advocated for comprehensive patient counseling that includes the full range of BMS options, not just those available within a provider’s immediate practice.

On the urinary side, Fosnight prioritizes pelvic floor physical therapy as a first-line intervention for incontinence, citing evidence of significant symptom improvement.

A recap of the FDA submissions and regulatory decisions in urology from July 2025.

A key diagnostic clue is that individuals with disordered eating often have unusually precise awareness of their food and fluid intake.

Beyond clinical metrics, Pezzella praised the device’s user-friendly, sophisticated design.